Survodutide vs. Mazdutide: Comparing Two GLP-1/Glucagon Dual Agonists in Development

Survodutide and mazdutide are often mentioned in the same breath because they work through the same basic mechanism: activating both the GLP-1 receptor and the glucagon receptor, rather than pairing GLP-1 with GIP the way tirzepatide does. But the two peptides come from unrelated companies, have been tested in different trial populations, and currently sit at very different points in the regulatory process.

Origins and Developers

Survodutide was originated by Zealand Pharma and is being developed and commercialized by Boehringer Ingelheim under a partnership agreement. Mazdutide was jointly developed by Innovent Biologics, a Chinese biotech, and Eli Lilly. Both are the same broad drug class, glucagon/GLP-1 receptor dual agonists, but the two molecules themselves are distinct compounds, not versions of the same drug.

Regulatory Status: The Biggest Difference

This is where the two diverge most sharply. Survodutide has not been approved anywhere; it remains in Phase 3 development globally, including in the SYNCHRONIZE trial program, and has received FDA breakthrough therapy designation specifically for MASH (metabolic dysfunction-associated steatohepatitis), a designation that speeds up FDA review but is not itself an approval. Mazdutide, by contrast, is already approved in China: first for chronic weight management in adults with obesity or overweight (June 2025), and later for glycemic control in adults with type 2 diabetes. Neither drug is FDA-approved in the United States.

What the Trial Data Shows

Survodutide's Phase 3 SYNCHRONIZE obesity trial reported weight loss of about 16.6%, with a separate pre-specified sub-analysis showing a 34% reduction in visceral fat and a 63% reduction in liver fat. Mazdutide's Chinese Phase 3 program (GLORY-1 and GLORY-2) has reported weight loss of up to roughly 20% at its highest studied dose, with GLORY-1 published in the New England Journal of Medicine, and a separate head-to-head trial (DREAMS-3) reporting an edge over semaglutide on weight loss and glycemic control.

It's tempting to look at those two numbers and conclude mazdutide outperforms survodutide, but that comparison isn't valid on its face. The trials differ in study population (global and diverse for survodutide's program versus exclusively Chinese adults for mazdutide's), trial design, dose selection, and duration. Without a head-to-head trial directly comparing the two drugs in the same population, differences in headline weight-loss percentages don't reliably indicate which drug is more effective.

Mechanism Nuance

Both drugs activate the glucagon receptor alongside GLP-1, a combination intended to add increased energy expenditure and fat oxidation on top of GLP-1's appetite-suppressing and glucose-regulating effects. The specific balance of GLP-1 versus glucagon receptor activity, and the resulting side-effect and efficacy profile, can differ between molecules even within the same mechanistic class, which is part of why regulators require full clinical programs for each drug individually rather than treating "dual agonist" as a single interchangeable category.

Availability

Because neither drug is FDA-approved, neither is legitimately available by prescription in the United States. Survodutide is only accessible through clinical trial enrollment in the US. Mazdutide is commercially available by prescription in China but not in the US through any regulated channel; any "mazdutide" or "survodutide" sold as a research peptide in the US falls outside FDA oversight and carries the same purity and quality risks common to that unregulated market.

The Bottom Line

Survodutide and mazdutide illustrate how quickly this drug class is moving, and how unevenly, across different regulatory systems. Survodutide has a well-documented global Phase 3 program but no approval anywhere yet; mazdutide already has real-world approval and use in China but hasn't yet gone through an FDA review. Anyone interested in either drug should track their progress through official regulatory and clinical trial channels, and discuss currently approved GLP-1 options with a physician rather than seeking either compound outside regulated medical care.